Ann: Chairman's Address and Presentation to AGM, page-189

A little research on what makes a successful biotech indicates there are two keys, a chief scientist that remains with the company and someone with the skills to commercialize the technology.
As highlighted, GC has demonstrated 8 years of complete inability to commercialize the science into revenue ( apart from for his own pocket) I genuinely believe his presence on the board is the company’s greatest risk.
If one listened to what Joe said at the AGM it is clear his intention to stay with ADO is dependent on competence at board level, it could be he has no confidence in GC .
My fear for ADO is that if GC gets anywhere near the steering wheel of this company again Joe will leave. Unlike GC, Joe was obviously very supportive of the disciplines and governance AS was bringing to ADO with his focus on addressing the failings of the company’s previous management approach.
With his track record of 8 years of inability to execute whether commercialising ADO’s products, capital raising, or company acquisition, GC’s credibility in the scientific and invesment community must be zero. I have no idea what possible value he could add to the board at this time.
GC’s campaign of ringing around shareholders to get them to vote AS down shows an extraordinary selfishness and fragile ego, not what is needed at the moment.
He needs to go.